ArticleIn vivo (Athens, Greece)
Association of the Modified ALBI Grade With Endoscopic Findings of Gastroesophageal Varices.
Article in In vivo (Athens, Greece). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- The Value of the ALBI and ALBI-PLT Scores in Predicting Esophageal Varices in Cirrhotic Patients: A Cross-Sectional Study.Health science reports · 2026Article
- Prognostic significance of modified albumin-bilirubin (MALBI) score in cirrhosis patients: A retrospective, single-center experience.Irish journal of medical science · 2026Article
- Low functional liver imaging score is associated with poor prognosis following hepatectomy for hepatocellular carcinoma.Scientific reports · 2024Article
- A Novel Nomogram for Predicting Early Rebleeding After Endoscopic Treatment of Esophagogastric Variceal Hemorrhage.Digestive diseases and sciences · 2024Article
- Role of albumin-bilirubin score in non-malignant liver disease.World journal of gastroenterology · 2024Article
- Albumin-bilirubin score in non-malignant liver diseases should be properly validated.World journal of gastroenterology · 2023Article
- Albumin‑bilirubin grade and INR for the prediction of esophagogastric variceal rebleeding after endoscopic treatment in cirrhosis.Experimental and therapeutic medicine · 2023Article
- Validation of the albumin-bilirubin score for identifying decompensation risk in patients with compensated cirrhosis.World journal of gastroenterology · 2023Article
- The ALBI score: From liver function in patients with HCC to a general measure of liver function.JHEP reports : innovation in hepatology · 2022Review
- Association of PNPLA3 SNP With the Development of HBV-related Hepatocellular Carcinoma.In vivo (Athens, Greece)Article
- Modification of the ALBI-PLT Score for the Prediction of High-risk Varices.In vivo (Athens, Greece)Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
aimThis study aimed to assess the association of the modified albumin-bilirubin (mALBI) grade with the endoscopic findings of gastroesophageal varices (GEVs). PATIENTS AND
methodsA total of 141 patients with histologically proven cirrhosis who underwent a liver biopsy and esophagogastroduodenoscopy were enrolled. The relationships between the mALBI grade and endoscopic findings were evaluated.
resultsThe incidence of GEVs and high-risk GEVs differed among mALBI grades. Patients with mALBI grades of 2b-3 had higher rates of GEVs and high-risk GEVs in comparison to those with mALBI grades of 1-2a (p<0.0001). In addition, patients with mALBI grade 2b or grade 3, but not those with mALBI grade 2a, had significantly higher rates of complicated GEVs and high-risk GEVs in comparison to those with mALBI grade 1.
conclusionThe mALBI grade may be useful in predicting the presence of GEVs and for stratifying their bleeding risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.